Autophagy has emerged as a key cellular process for organellar quality control, yet this pathway apparently fails to eliminate mitochondria containing pathogenic mutations in mitochondrial DNA (mtDNA) in patients with a variety of human diseases. In order to explore how mtDNA-mediated mitochondrial dysfunction interacts with endogenous autophagic pathways, we examined autophagic status in a panel of human cytoplasmic hybrid (cybrid) cell lines carrying a variety of pathogenic mtDNA mutations. We found that both genetic-and chemically induced loss of mitochondrial transmembrane potential (Dc m ) caused recruitment of the pro-mitophagic factor Parkin to mitochondria. Strikingly, however, the loss of Dc m alone was insufficient to prompt delivery of mitochondria to the autophagosome (mitophagy). We found that mitophagy could be induced following treatment with the mTORC1 inhibitor rapamycin in cybrids carrying either largescale partial deletions of mtDNA or complete depletion of mtDNA. Further, we found that the level of endogenous Parkin is a crucial determinant of mitophagy. These results suggest a two-hit model, in which the synergistic induction of both (i) mitochondrial recruitment of Parkin following the loss of Dc m and (ii) mTORC1-controlled general macroautophagy is required for mitophagy. It appears that mitophagy can be accomplished by the endogenous autophagic machinery, but requires the full engagement of both of these pathways.
INTRODUCTION
The human mitochondrial genome is a 16.6 kb circle of double-stranded DNA (mtDNA) (1) . Point mutations in mtDNA cause maternally inherited diseases, including neuropathy, ataxia and retinitis pigmentosa (NARP), and mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS) (reviewed in 2). Large-scale (kilobasesized) partial deletions of mtDNA (D-mtDNAs), in which a portion of the circular mtDNA is lost, are typically associated with Kearns -Sayre syndrome (KSS) (2) . High levels of D-mtDNAs are also found in the substantia nigra of patients with Parkinson disease (PD) and in normal aging (3, 4) .
Autophagy is a major cellular quality control mechanism for the selective degradation of large-scale protein aggregates and organelles, including mitochondria (5) . Despite the ability of autophagy to degrade non-functional mitochondria (5), the very existence, persistence and even accumulation of pathogenic mtDNA mutations in human patients imply that selective removal of mitochondria containing pathogenic mtDNAs is not occurring to any appreciable extent. The reason for the failure of the autophagic machinery to recognize these organelles is unknown.
Macroautophagy is the process by which an isolation membrane forms around cellular components, engulfing them within the autophagosome, which subsequently fuses with hydrolase-containing lysosomes that break down the engulfed materials (6) . This process is controlled directly by the mammalian target of rapamycin (mTOR): active mTOR is complexed with its interacting partner Raptor and associated * To whom correspondence should be addressed at: Department of Neurology, Room P&S 4-449, Columbia University Medical Center, 630 West 168th Street, New York, NY 10032, USA. Tel: +1 2123051665; Fax: +1 2123053986; Email: eas3@columbia.edu factors (7) [termed mTORC1, differentiating it from the mTOR/Rictor (8), or mTORC2, complex], activating a kinase signaling cascade that promotes cellular proliferation while simultaneously inhibiting autophagy (reviewed in 9,10). Under autophagic conditions, however, mTORC1 assumes a kinase-inhibited conformation (7) , initiating autophagosome formation (11) . Macroautophagy can thus result in a general, nonspecific sequestration of cytoplasm within autophagosomes, or in the specific selective degradation of different organelles (12) .
Selective targeting of mitochondria for autophagy involves PARK6 [protein PINK1 (PTEN-induced kinase 1)] and PARK2 (Parkin, an E3 ubiquitin ligase), both of which can be mutated in familial PD (13, 14) . Experimental chemical uncoupling of the mitochondrial transmembrane potential (Dc m ) causes the translocation of PINK1 to the mitochondrial outer membrane (MOM) (15) (16) (17) , leading to recruitment of Parkin from the cytosol to the MOM (15) . Following the Parkin-mediated ubiquitination of mitochondrial porin (18) and mitofusins 1 and 2 (16) , these substrates are then bound by p62, a key factor in selective autophagy (19) , which then delivers mitochondria to the autophagosome via interaction with microtubule-associated light-chain 3 (LC3) (18) .
Despite the known pathogenic nature of mtDNA mutations, it is unknown why intrinsic autophagic pathways do not eliminate these naturally occurring forms of dysfunctional mitochondria, although the fact that patient cells typically harbor a mixture of wild-type and mutant mtDNAs (heteroplasmy) might explain, at least in part, the lack of an autophagic response. If true, cells carrying only mutated mtDNAs (homoplasmy) should have increased steady-state autophagy relative to WT cells. We therefore assayed autophagy in a battery of homoplasmic cybrid cell lines repopulated with different patient-derived pathogenic mutant mtDNAs. Surprisingly, the genetic loss of mitochondrial function in these cells did not increase intrinsic steady-state levels of autophagy, but we discovered that widespread mitophagy (defined here as delivery of mitochondria to the autophagosome) could be induced in response to two conditions: (i) the loss of Dc m , resulting in recruitment of Parkin to the organelle, and (ii) the activation of macroautophagy, through the inhibition of mTORC1 signaling.
RESULTS

Cells carrying mtDNA mutations do not have elevated levels of macroautophagy
We employed a panel of cybrid cell lines, in which a human 143B osteosarcoma nuclear background was depleted of all endogenous mtDNA (20) and repopulated with patient-derived mtDNAs (21) . The WT (FLP6a39.2), D (FLP6139.32), A3243G (RN164), T8993G (JCP261) and r 0 (143B206) cell lines have been described previously (21) (22) (23) . Briefly, the WT cell line carries homoplasmic WT-mtDNA; the D cell line is homoplasmic for a 1.9 kb D-mtDNA from a patient with KSS; the A3243G cell line is homoplasmic for its respective point mutation derived from a patient with MELAS; the T8993G cell line is homoplasmic for a point mutation derived from a patient with NARP; and the r 0 cell line is depleted of all mtDNA (Table 1) .
We infected each cell line with a lentivirus containing LC3-GFP (24) and established clonal cultures to ensure consistent LC3-GFP expression. Cytosolic LC3-I is recruited to the autophagosome upon the induction of autophagy via conjugation to phosphatidylethanolamine, producing the autophagic LC3-II form (6) . When fused to GFP ( 27 kDa), the two LC3 forms migrate on gels with apparent molecular weights of 43 and 41 kDa, respectively. In western blots of cells expressing LC3-GFP-II, a band of 27 kDa is also observed, as fusion of the autophagosome with the lysosome results in cleavage of LC3-GFP-II, producing 'free' GFP as an additional marker of autophagy (25) . When visualized by fluorescence microscopy, LC3-GFP-I is present diffusely in the cytosol; upon autophagic induction, LC3-GFP-I is processed to LC3-GFP-II and recruited to autophagosomes as discrete punctae, providing a useful visual marker of autophagosomes (26, 27) .
Upon anti-GFP western blotting of lysates from the cybrid cell lines, we observed a predominant band for cytosolic LC3-GFP-I at 43 kDa in all samples (Fig. 1A) . We also observed bands corresponding to the autophagic LC3-GFP-II ( 41 kDa) and free GFP ( 27 kDa) species, but at lower levels [i.e. a ratio of (LC3-GFP-II + free GFP)/(LC3-GFP-I) of 0.2-0.5], with D cells showing a (non-significant) 2.5-fold higher ratio than WT (Fig. 1B, gray bars) . In agreement with the western blotting, live-cell fluorescence microscopy revealed that none of the cell lines examined had any appreciable proliferation of autophagosomes (Supplementary Material, Fig. S1A, upper panels) . Even though the D cells had increased amounts of autophagic LC3-GFP-II and free GFP (Fig. 1A) , confocal fluorescence microscopy showed that there was no difference between WT and D cells in the number or size of the LC3-GFP punctae ( Fig. 1C and D) . Thus, our data indicate that there is no increase in autophagy in cells carrying mtDNA mutations relative to WT cells. Western blotting against endogenous LC3 revealed that both D and r 0 cells actually have decreased endogenous LC3 levels, compared with two independently derived WT lines (Supplementary Material, Fig. S1D ).
Rapamycin challenge reveals increased macroautophagy in D cells
As none of the cloned cybrid lines had elevated levels of autophagosomes, we asked whether they could respond to an (Fig. 1A and B, black bars). We obtained similar results both by LC3-GFP fluorescence microscopy (Supplementary Material, Fig. S1A , lower panels) and by immunolabeling against endogenous LC3-II (Supplementary Material, Fig. S1C ). Using confocal fluorescence microscopy, compared with untreated cells, neither rapamycin-treated WT nor D cells showed significant increases in the number of autophagosomes per cell, but rapamycin-treated D cells displayed an increase in the average size of autophagosomes (61 + 5 versus 27 + 10 pixels in untreated D cells) (Fig. 1D) , reflecting a proliferation of numerous large LC3-GFP punctae (Fig. 1C) . Similar results were obtained using uncloned mass culture of LC3-GFP-infected WT and D cybrids (Supplementary Material, Fig. S1E ), indicating that these results were not confined to any particular clonal cell line. To determine the nature of this increased autophagosomal content, we examined D cell response to chloroquine, an inhibitor of autophagosomal degradation (28) (Fig. 1D) ; strikingly, many of these abnormally large structures were MitoTrackerpositive ( Fig. 2A, arrowheads) , indicating that these autophagosomes had indeed engulfed mitochondria. Quantitative image analysis revealed that the rapamycin-treated D cells had, on average, 23 + 7% of their total mitochondria colocalizing with autophagosomes, compared with just 4 + 2% for untreated D cells, which was similar to the value in rapamycintreated WT cells (5 + 1%) (Fig. 2B) . Collectively, these findings demonstrate robust uptake of mitochondria by autophagosomes in rapamycin-treated D cells.
We examined the involvement of the mitochondrial-specific Parkin and p62 autophagic factors in this mitophagy. Following treatment with rapamycin, GFP-Parkin was recruited to mitochondria of D cells (Fig. 3A) . WT cells showed a diffuse GFP fluorescence throughout the cell that was essentially unchanged upon treatment with rapamycin. Untreated D cells showed a mosaic distribution of fluorescence, with immunolabeling showed a strong signal only in rapamycintreated D cells, appearing as large punctae which frequently colocalized with mitochondria ( Fig. 3B , arrowheads). Moreover, p62 immunolabeling also showed colocalization with LC3-GFP autophagosomes in rapamycin-treated D cells (Fig. 3C, arrowheads) . These experiments demonstrate that the autophagic uptake of mitochondria in rapamycin-treated D cells was mediated by Parkin and p62. Since Parkin-mediated mitophagy would presumably require the loss of Dc m (15-17), we examined basal Dc m in the cybrid lines using tetramethyl rhodamine ester (TMRE). Notably, D cells had the lowest TMRE fluorescence of all the cell lines studied ( Fig. 4A and B) . WT cells maintained an average peak fluorescence intensity of 446 + 194 U, whereas D and r 0 cells [both with essentially no respiratory chain function (21)] maintained low peak TMRE values (138 + 53 and 234 + 70, respectively), similar to values in which Dc m was dissipated completely by the protonophore uncoupler carbonyl cyanide Human
when challenged with rapamycin. Accordingly, we examined mTORC1 signaling, which controls macroautophagy, in our cells. When mTORC1 kinase signaling is active (i.e. macroautophagy is repressed), downstream targets are phosphorylated, including the ribosomal S6 protein (33) . In all CCCP-treated WT cells, we observed a strong band for phospho-S6 (Fig. 5A) , consistent with the lack of autophagic induction in response to CCCP treatment observed above. We then monitored mTORC1 signaling in our panel of mutant cybrids, including the rapamycin-treated D cells that had displayed robust autophagic induction. In agreement with our previous results (Fig. 1) , all untreated cell lines maintained a strong phospho-S6 signal, indicating that mTORC1-mediated signaling was active (Fig. 5B) , precluding the induction of macroautophagy. However, in rapamycintreated cells, none of the samples exhibited a signal for phospho-S6, indicating a complete inhibition of mTORC1 signaling, allowing for the induction of macroautophagy (Fig. 5B) . In spite of the derepression of mTORC1 in all of our cell lines, autophagy was induced only in the D cells, but not in the WT, T8993G, A3243G or r 0 cells, indicating that mTORC1 inhibition alone is not sufficient to induce mitochondrial autophagy.
Thus, neither the loss of Dc m alone nor the inhibition of mTORC1 alone was sufficient to induce mitophagy in D cells; both were required. 
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Human Molecular Genetics, 2012, Vol. 21, No. 5 rapamycin treatment, might recapitulate the autophagic phenotype in a WT mtDNA background. As expected, neither treatment of WT cells with 10 mM CCCP alone nor with 250 nM rapamycin alone yielded the proliferation of large autophagosomes that we saw in rapamycin-treated D cells (Fig. 6A and B) . Contrary to our expectations, however, treatment first with rapamycin for 48 h followed by CCCP for 1 h also did not show autophagic induction (Fig. 6A and B) . We therefore attempted to mimic more closely the constitutive loss of Dc m in D cells by incubating WT cells first with CCCP for 1 h and then treating the cells with rapamycin for 48 h in the presence of CCCP, but in spite of the presence of both agents, autophagic induction was still minimal (Fig. 6C and D) . When we examined the WT cells that had been treated with CCCP for short (1 h) or long (49 h We therefore used quantitative reverse transcription PCR (qRT-PCR) to examine PINK1 and Parkin mRNA expression in our panel of cybrids (endogenous levels of these proteins are very low and thus difficult to observe with antibodies), both constitutively and in response to rapamycin. WT cells contained ample amounts of PINK1 and Parkin [more than four times as much as in human SH-SY5Y or HeLa cells (34, 35) ]. However, basal endogenous transcript levels of PINK1 were significantly lower than WT in several of the mtDNA mutant cybrids: an average of 15% of WT in T8993G, 26% in A3243G and 36% in r 0 cells (Fig. 7A) . Similarly, basal expression of Parkin was frequently lower: 47% in D, 35% in T8993G and only 21% in r 0 cells (Fig. 7A) . Treatment with rapamycin did not result in significant changes in these levels (Supplementary Material, Fig. S4A and B) .
Thus, the lack of autophagy in WT cells was probably due not to low levels of PINK1 or Parkin but rather to high Dc m . However, the lack of autophagy in r 0 cells (with low Dc m )
could indeed have been due to low levels of PINK1 and Parkin expression, as r 0 cells had dramatically decreased levels of these factors. We therefore examined the ability of the different cybrid lines to recruit Parkin to mitochondria (Supplementary Material, Fig. S4C ). Upon transfection with GFP-Parkin, we found that both D and r 0 cells had increased proportions of cells with mitochondrial recruitment of Parkin (39 and 37%, respectively) compared with WT cells transfected in a similar manner (1%) (Fig. 7B) . As expected, there was little recruitment of GFP-Parkin in the A3243G and T8993G cells (Fig. 7A) As Parkin is genetically downstream of PINK1 (36), we therefore overexpressed GFP-Parkin in r 0 cells to ask whether increasing Parkin levels could induce the formation of autophagosomes like that seen in rapamycin-treated D cells. As expected, in the absence of exogenous Parkin, rapamycin-treated WT and r 0 cells showed very few cytoplasmic LC3-GFP autophagosomes, whereas rapamycin-treated D cells showed a characteristic proliferation of large autophagosomes (Fig. 7C) . Strikingly, however, Parkin-transfected r 0 cells showed a marked proliferation of LC3-GFP autophagosomes in response to rapamycin treatment (Fig. 7C) . Quantitation of LC3-GFP punctae per cell and average puncta size (Fig. 7D) confirmed that the addition of Parkin to r 0 cells results in an autophagic phenotype identical to that seen in rapamycin-treated D cells. Microscopic analysis of the LC3-GFP autophagosomes in Parkin-expressing r 0 cells revealed that these autophagosomes frequently colocalized to mitochondria, with concomitant Parkin recruitment to those organelles (Fig. 7E ). In agreement with Suen et al. (37) , these results suggest that r 0 cells are essentially similar to D cells in terms of mitophagic induction; they merely have less endogenous Parkin.
DISCUSSION
Our data indicate that widespread mitophagy (defined here as mitochondria sequestered within autophagosomes) can be achieved in cells carrying mtDNA mutations, and that the level of Parkin is critically important to the cell's ability to undergo mitophagy. Strikingly, the loss of Dc m , in and of itself, is not sufficient to activate mitophagy: the mitophagic response requires the synergistic activation of (i) the loss of Dc m (activating recruitment of Parkin to mitochondria) and (ii) rapamycin-mediated inhibition of mTORC1 signaling (activating general macroautophagy), in order to accomplish robust autophagic sequestration of dysfunctional mitochondria. Our results indicate that a crucial distinction exists between recruitment of Parkin to mitochondria (due to the loss of Dc m ) and uptake of mitochondria within autophagosomes (true mitophagy). In other words, although the loss of Dc m is necessary for mitophagy, it is not sufficient.
Human Molecular
We find that mtDNA mutations resulting in the loss of Dc m cause increased recruitment of Parkin to mitochondria, consistent with and extending recent studies demonstrating that chemical dissipation of Dc m results in recruitment of Parkin to mitochondria (15, 17, 35) . However, our studies suggest that the loss of Dc m alone, whether chemically induced or as a result of mtDNA mutation, does not induce the formation of autophagosomes to any appreciable extent. Basally, cells carrying D-mtDNAs did not have a significantly greater number or size of autophagosomes than did WT cells. We also found that the addition of CCCP to WT cells failed to induce the proliferation of autophagosomes, mirroring findings in cortical neurons (38) . These findings are consistent with the observation that D-mtDNAs, which cause reduced Dc m , can exist in patients without being degraded [in fact, they are often amplified preferentially to those containing 
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WT-mtDNA (2)]. These data argue that an additional signaling requirement exists for autophagic degradation of mitochondria in vivo.
One such requirement appears to be the activation of macroautophagy, via the inhibition of mTORC1 signaling. It was only when mTORC1 was inhibited via rapamycin that we observed a proliferation of autophagosomes containing mitochondria. Interestingly, although we examined a series of different pathogenic mtDNA mutations, only D cells (with low Dc m ), but not A3243G or T8993G cells (with relatively high Dc m ), showed a robust induction in response to rapamycin. Thus, the loss of mitochondrial function per se [i.e. impaired respiratory chain function (A43243G) or reduced ATP synthesis (T8993G)] is apparently not an important determinant in recruiting pro-mitophagic factors to mitochondria, consistent with recent findings showing a similar lack of mitochondrial Parkin recruitment in mice with transgenic loss of mitochondrial function (39) .
A challenge to the 'two-hit' model proposed above (i.e. the loss of Dc m plus derepression of mTORC1) is our finding that the reduction of Dc via CCCP treatment of WT cells in conjunction with rapamycin treatment failed to result in a robust mitophagic phenotype, as had been seen in rapamycin-treated D cells. There are at least two reasons that might explain this discrepancy. First, protonophores like CCCP dissipate Dc across all polarized cellular membranes, not just mitochondrial membranes. In particular, besides depolarizing the plasma membrane (40) and mitochondria, protonophores have been shown to depolarize lysosomes and to inhibit lysosomal acidification (32, 41) , which is necessary for autophagic degradation. Second, mtDNA mutations represent a constitutive, mitochondrial-specific loss of Dc m : these cells lack fully assembled respiratory complexes (42) and show increased mitochondrial ubiquitination (43) , whereas CCCP-treated cells do not (44) . Thus, we feel that this discrepancy underscores a distinction between the pharmacological dissipation of overall membrane potential by a protonophore and the mitochondrial-specific loss of Dc m due to authentic mtDNA mutations.
In support of this view, although it has been elegantly and comprehensively shown that CCCP treatment of various cell lines causes recruitment of Parkin to otherwise-normal mitochondria (15) (16) (17) , it has not, in fact, been demonstrated convincingly that such treatment results in widespread delivery of those mitochondria to autophagosomes. In the one study in which quantitative results were reported (15) , CCCP treatment of Parkin-overexpressing HeLa cells [containing approximately 400-800 mitochondria (45) ] resulted in only 1 -2% of the organelles colocalizing with LC3, a value that contrasts with the 23% of mitochondria colocalizing with LC3 in D cells (Fig. 2B) .
Our results also demonstrate the importance of Parkin levels to the cell's ability to undergo mitophagy. Initially, we had expected that r 0 cells (with a low Dc m , similar to that in D cells) would display mitophagy when challenged with rapamycin, as D cells did. However, we subsequently determined that r 0 cells had the lowest basal level of Parkin transcripts of all examined cell lines. When exogenous Parkin was expressed in r 0 cells, we found that they were able to recruit Parkin to mitochondria and they responded to rapamycin treatment with a mitophagic phenotype identical to that found in rapamycintreated D cells. These experiments highlight the importance of Parkin expression to the cell's ability to undergo mitophagy.
Most mechanistic studies of mitochondrial autophagy to date have relied on overexpression of PINK1 and Parkin (37), but relatively little is known about the intrinsic biology of these two factors. In our analysis of the relative levels of PINK1 and Parkin mRNAs in cybrids, mtDNA mutant cell lines, regardless of the specific mtDNA defect, had decreased steady-state levels of these transcripts relative to WT cells. Similarly, we found that cells carrying D-mtDNAs, as well as r 0 cells, showed decreased levels of endogenous LC3. Knockdown of PINK1 results in mitochondrial dysfunction (46) . Our findings suggest that the converse may also be true: mtDNA-mutant cells have depressed PINK1 and Parkin expression, as well as decreased endogenous LC3 levels. These data suggest that mtDNA-based mitochondrial dysfunction represses transcription of pro-mitophagic factors, although the mechanism by which this 'retrograde' signaling occurs is currently unknown.
These experiments demonstrate the physiological potential of mitophagy as a therapeutic strategy to treat mitochondrial diseases, such as KSS, and neurodegenerative disorders, such as PD. High levels of D-mtDNAs in substantia nigra neurons of both normal aged individuals (4) and PD patients (3) suggest that the accumulation of D-mtDNAs may combine with environmental insults and other nuclear mutations to elicit neuronal cell death. We note that gene profiling of dopaminergic neurons from patients with sporadic PD revealed a decrease in PINK1 and Parkin expression (47), mirroring the expression of these factors observed here. This loss of mitophagic factors may contribute to the persistence of pathogenic mtDNAs in patients. Thus, therapeutic approaches in PD employing pro-autophagic agents such as rapamycin may induce autophagic degradation of mitochondria carrying D-mtDNAs (48) .
In summary, our findings suggest a 'two-hit' model for mitochondrial autophagy: (i) the activation of mitophagic targeting (via the loss of Dc m ) and (ii) the activation of general macroautophagy (via mTORC1 inhibition). These studies indicate that mtDNA-mediated mitochondrial dysfunction has retrograde signaling effects on pro-mitophagic factors such as PINK1, Parkin and LC3, and that the endogenous autophagic machinery is sufficient for autophagy of mitochondria carrying D-mtDNAs. These findings provide a mechanistic basis for mitochondrial autophagy, suggesting that pro-autophagic strategies may be effective against diseases associated with D-mtDNAs, such as KSS and PD, using the activation of endogenous autophagic pathways against physiological forms of mitochondrial dysfunction.
MATERIALS AND METHODS
Cell culture
Cells were grown in Dulbecco's high-glucose MEM (Gibco) with 10% FBS (Invitrogen) and supplemented with 10 mg/ml uridine (Sigma) at 378C and 5% CO 2 . Lentiviral LC3-GFP infection was performed as described previously (24) . LC3-GFP-expressing clonal cybrid lines were isolated using Human Molecular Genetics, 2012, Vol. 21, No. 5 987 cloning rings (Scienceware). Rapamycin, chloroquine diphosphate salt and CCCP were from Sigma. Cells were seeded at 50 000 cells per well in six-well dishes and allowed to recover overnight prior to treatment. Unless otherwise indicated, all rapamycin treatments were for 48 h at 250 nM. For flow cytometry, 500 000 cells were seeded to 6 cm-diameter dishes overnight, followed by 20 min incubation with 2.5 nM TMRE, washed and analyzed using an LSRII Cell Analyzer (50 000 events per trial).
Fluorescence microscopy
Cells were incubated with MitoTracker Red CMXRos or LysoTracker Red (Invitrogen) for 30 min, washed and fixed with 4% paraformaldehyde in PBS for 30 min. Immunofluorescence microscopy used anti-p62 monoclonal antibody (Abcam 56416), anti-TOM20 polyclonal antibody (Santa Cruz sc-11415) or anti-LC3B polyclonal antibody (Sigma L7543) in conjunction with AlexaFluor-conjugated goat antimouse and goat anti-rabbit secondary antibodies (Invitrogen). Cover slips were mounted with 50% glycerol in PBS. Confocal microscopy utilized a Zeiss LSM510 META inverted confocal microscope with a 40× oil immersion objective. Confocal images were adjusted equally using ImageJ. Conventional oil immersion and live-cell imaging used an Olympus IX70 inverted fluorescence microscope and SPOT RT digital camera. Image quantitation was performed using MetaMorph. Images were processed equally. For TMRE, live-cell imaging was conducted by incubating cells in 2.5 nM TMRE for 20 min, followed by direct visualization.
Western blotting
Cell lysates were washed with PBS and lysed in cold RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 0.1% SDS) on ice for 5 min. Lysates (20 mg protein) were run on a 10% SDS -PAGE gel overnight at 25 V, 48C. Proteins were transferred to ZetaProbe PVDF (Bio-Rad) for 1 h at 100 V, 48C. Blots were probed with anti-GFP monoclonal antibody JL-8 (Clontech), anti-phospho ribosomal S6 monoclonal antibody (Cell Signaling, Catalog No. 2215), or anti-tubulin (Sigma) at 1:1000 dilution in PBS overnight at 48C, followed by incubation with horseradish peroxidase-conjugated goat anti-mouse antibody (Amersham). Blots were developed using WestDura Extended Duration Substrate (Thermo Scientific) and exposed films developed on a Kodak X-Omat. Western blot quantification was performed using ImageJ.
Quantitative reverse transcription cDNAs were produced using SuperScriptw First-Strand Synthesis System (Invitrogen). An amount of 50 ng of cDNAs were run in reactions using PINK1, Parkin and actin primers from Qiagen (Hs_PINK1_2_SG QT01670459, Hs_PARK2_va.1_SG QT01005571, Hs_ACTB_2_SG QT01680476) with Power SYBR w Green PCR Master Mix (Applied Biosystems) for 40 cycles.
Statistical analysis
Differences among means were analyzed using one-or two-way repeated measure analysis of variance (ANOVA). When ANOVA showed significant differences, pair-wise comparisons between means were tested by the Newman -Keuls post hoc testing, whereas comparisons against the control group were tested by the Dunnett post hoc testing. In all analyses, the null hypothesis was rejected at the 0.05 level. All statistical analyses were performed using SigmaStat for Windows 3.5.
